# Celldex Therapeutics, Inc.: financial statements, quarterly

CLDX · Nasdaq · CIK 744218 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cldx.md) · [Financials](/companies/cldx/financials.md) · [Filings](/companies/cldx/filings.md) · [Insiders](/companies/cldx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cldx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1.5](/filings/0001410578-24-001766.md) | [4.1 d](/filings/0001104659-26-019652.md) | [0.2](/filings/0001410578-25-001111.md) | [2.5](/filings/0001410578-25-001610.md) | [3.2](/filings/0001104659-25-109137.md) | [1.2 d](/filings/0001104659-26-019652.md) | [0.7](/filings/0001104659-26-057113.md) | [0.7](/filings/0001104659-26-091984.md) | [0.0 d](/filings/0001104659-25-109137.md) | [0.1 d](/filings/0001104659-26-019652.md) | [0.0](/filings/0001104659-26-057113.md) | [0.0](/filings/0001104659-26-091984.md) |
| Research and development | $m | [34.5](/filings/0001410578-24-001766.md) | [30.4 d](/filings/0001104659-26-019652.md) | [31.7](/filings/0001410578-25-001111.md) | [39.7](/filings/0001410578-25-001610.md) | [45.3](/filings/0001104659-25-109137.md) | [46.9 d](/filings/0001104659-26-019652.md) | [52.6](/filings/0001104659-26-057113.md) | [54.2](/filings/0001104659-26-091984.md) | [62.9](/filings/0001104659-25-109137.md) | [75.3 d](/filings/0001104659-26-019652.md) | [73.0](/filings/0001104659-26-057113.md) | [67.5](/filings/0001104659-26-091984.md) |
| Operating income | $m | [(41.2)](/filings/0001410578-24-001766.md) | [(47.6) d](/filings/0001104659-26-019652.md) | [(40.6)](/filings/0001410578-25-001111.md) | [(46.3)](/filings/0001410578-25-001610.md) | [(52.1)](/filings/0001104659-25-109137.md) | [(56.0) d](/filings/0001104659-26-019652.md) | [(62.7)](/filings/0001104659-26-057113.md) | [(63.9)](/filings/0001104659-26-091984.md) | [(73.6)](/filings/0001104659-25-109137.md) | [(87.2) d](/filings/0001104659-26-019652.md) | [(84.4)](/filings/0001104659-26-057113.md) | [(80.6)](/filings/0001104659-26-091984.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(38.3)](/filings/0001410578-24-001766.md) | [(43.3) d](/filings/0001104659-26-019652.md) | [(32.8)](/filings/0001104659-25-109137.md) | [(35.8)](/filings/0001104659-25-109137.md) | [(42.1)](/filings/0001104659-25-109137.md) | [(47.1) d](/filings/0001104659-26-019652.md) | [(53.8)](/filings/0001104659-26-091984.md) | [(56.6)](/filings/0001104659-26-091984.md) | [(67.0)](/filings/0001104659-25-109137.md) | [(81.3) d](/filings/0001104659-26-019652.md) | [(78.7)](/filings/0001104659-26-091984.md) | [(73.5)](/filings/0001104659-26-091984.md) |
| Diluted EPS | $ per share | [(0.81)](/filings/0001410578-24-001766.md) | not reported | [(0.56)](/filings/0001410578-25-001111.md) | [(0.54)](/filings/0001410578-25-001610.md) | [(0.64)](/filings/0001104659-25-109137.md) | not reported | [(0.81)](/filings/0001104659-26-057113.md) | [(0.85)](/filings/0001104659-26-091984.md) | [(1.01)](/filings/0001104659-25-109137.md) | not reported | [(1.18)](/filings/0001104659-26-057113.md) | [(0.94)](/filings/0001104659-26-091984.md) |
| Basic EPS | $ per share | [(0.81)](/filings/0001410578-24-001766.md) | not reported | [(0.56)](/filings/0001410578-25-001111.md) | [(0.54)](/filings/0001410578-25-001610.md) | [(0.64)](/filings/0001104659-25-109137.md) | not reported | [(0.81)](/filings/0001104659-26-057113.md) | [(0.85)](/filings/0001104659-26-091984.md) | [(1.01)](/filings/0001104659-25-109137.md) | not reported | [(1.18)](/filings/0001104659-26-057113.md) | [(0.94)](/filings/0001104659-26-091984.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: not reported
- Net income: us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic, us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [21.1](/filings/0001410578-23-002169.md) | [34.8](/filings/0001410578-25-000216.md) | [115](/filings/0001410578-24-000593.md) | [42.7](/filings/0001410578-24-001219.md) | [36.4](/filings/0001410578-24-001766.md) | [28.4](/filings/0001104659-26-019652.md) | [17.1](/filings/0001410578-25-001111.md) | [23.0](/filings/0001410578-25-001610.md) | [36.0](/filings/0001104659-25-109137.md) | [28.9](/filings/0001104659-26-091984.md) | [35.7](/filings/0001104659-26-057113.md) | [47.5](/filings/0001104659-26-091984.md) |
| Current assets | $m | [246](/filings/0001410578-23-002169.md) | [432](/filings/0001410578-25-000216.md) | [835](/filings/0001410578-24-000593.md) | [812](/filings/0001410578-24-001219.md) | [779](/filings/0001410578-24-001766.md) | [747](/filings/0001104659-26-019652.md) | [694](/filings/0001410578-25-001111.md) | [648](/filings/0001410578-25-001610.md) | [604](/filings/0001104659-25-109137.md) | [535](/filings/0001104659-26-091984.md) | [459](/filings/0001104659-26-057113.md) | [725](/filings/0001104659-26-091984.md) |
| Total assets | $m | [280](/filings/0001410578-23-002169.md) | [466](/filings/0001410578-25-000216.md) | [869](/filings/0001410578-24-000593.md) | [846](/filings/0001410578-24-001219.md) | [823](/filings/0001410578-24-001766.md) | [792](/filings/0001104659-26-019652.md) | [739](/filings/0001410578-25-001111.md) | [692](/filings/0001410578-25-001610.md) | [648](/filings/0001104659-25-109137.md) | [583](/filings/0001104659-26-091984.md) | [511](/filings/0001104659-26-057113.md) | [782](/filings/0001104659-26-091984.md) |
| Current liabilities | $m | [27.8](/filings/0001410578-23-002169.md) | [31.1](/filings/0001410578-25-000216.md) | [26.3](/filings/0001410578-24-000593.md) | [27.7](/filings/0001410578-24-001219.md) | [32.1](/filings/0001410578-24-001766.md) | [39.5](/filings/0001104659-26-019652.md) | [32.0](/filings/0001410578-25-001111.md) | [33.0](/filings/0001410578-25-001610.md) | [46.5](/filings/0001104659-25-109137.md) | [51.0](/filings/0001104659-26-091984.md) | [51.5](/filings/0001104659-26-057113.md) | [61.3](/filings/0001104659-26-091984.md) |
| Total liabilities | $m | [33.5](/filings/0001410578-23-002169.md) | [36.5](/filings/0001410578-25-000216.md) | [30.2](/filings/0001410578-24-000593.md) | [31.9](/filings/0001410578-24-001219.md) | [37.3](/filings/0001410578-24-001766.md) | [45.3](/filings/0001104659-26-019652.md) | [36.5](/filings/0001410578-25-001111.md) | [37.0](/filings/0001410578-25-001610.md) | [50.1](/filings/0001104659-25-109137.md) | [55.8](/filings/0001104659-26-091984.md) | [55.0](/filings/0001104659-26-057113.md) | [67.8](/filings/0001104659-26-091984.md) |
| Shareholders' equity | $m | [247](/filings/0001410578-24-001766.md) | [429](/filings/0001104659-26-019652.md) | [839](/filings/0001104659-25-109137.md) | [814](/filings/0001104659-25-109137.md) | [786](/filings/0001104659-25-109137.md) | [747](/filings/0001104659-26-091984.md) | [703](/filings/0001104659-26-091984.md) | [655](/filings/0001104659-26-091984.md) | [598](/filings/0001104659-25-109137.md) | [527](/filings/0001104659-26-091984.md) | [456](/filings/0001104659-26-091984.md) | [715](/filings/0001104659-26-091984.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(19.0) d](/filings/0001410578-24-001766.md) | [(32.5) d](/filings/0001104659-26-019652.md) | [(40.6)](/filings/0001410578-25-001111.md) | [(29.3) d](/filings/0001410578-25-001610.md) | [(55.3) d](/filings/0001104659-25-109137.md) | [(32.5) d](/filings/0001104659-26-019652.md) | [(54.4)](/filings/0001104659-26-057113.md) | [(44.0) d](/filings/0001104659-26-091984.md) | [(48.6) d](/filings/0001104659-25-109137.md) | [(63.9) d](/filings/0001104659-26-019652.md) | [(65.6)](/filings/0001104659-26-057113.md) | [(57.4) d](/filings/0001104659-26-091984.md) |
| Capital expenditure | $m | [0.2 d](/filings/0001410578-24-001766.md) | [0.7 d](/filings/0001104659-26-019652.md) | [0.3](/filings/0001410578-25-001111.md) | [0.3 d](/filings/0001410578-25-001610.md) | [0.5 d](/filings/0001104659-25-109137.md) | [0.8 d](/filings/0001104659-26-019652.md) | [0.3](/filings/0001104659-26-057113.md) | [0.7 d](/filings/0001104659-26-091984.md) | [0.4 d](/filings/0001104659-25-109137.md) | [1.3 d](/filings/0001104659-26-019652.md) | [1.6](/filings/0001104659-26-057113.md) | [3.2 d](/filings/0001104659-26-091984.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [0.0](/filings/0001410578-23-002169.md) | [0.0](/filings/0001410578-24-000593.md) | [0.0](/filings/0001410578-24-001219.md) | [0.0](/filings/0001410578-24-001766.md) | [0.1](/filings/0001410578-25-001111.md) | [0.1](/filings/0001410578-25-001610.md) | [0.1](/filings/0001104659-25-109137.md) | [66.4](/filings/0001104659-26-057113.md) | [66.4](/filings/0001104659-26-091984.md) | [0.1](/filings/0001104659-25-109137.md) | [66.6](/filings/0001104659-26-057113.md) | [77.8](/filings/0001104659-26-091984.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 78,529,532 at 2026-07-29, from the cover of the [10-Q filed 2026-08-06](/filings/0001104659-26-091984.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:23 ET. No prices; not investment advice.